Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 501 - 550 out of 111,378

Document Document Title
WO/2016/020853A1
The invention describes the preparation of new cocoa bean and grape seed extracts and their use, and use of their mixtures in the treatment of various human pathological conditions, such as vascular diseases, cognitive disorders, depress...  
WO/2016/021835A1
The present invention relates to a preparation method of drug-containing sustained release microparticles, the preparation method comprising the steps of: (a) dissolving a biodegradable polymer and a drug in a halogenated alkane solvent ...  
WO/2016/020307A1
Novel compounds for use in cognition improvement It relates to certain compounds having a polycyclic structure and a -(C=O)NRaRb moiety, wherein the polycyclic structure comprises at least three ring systems, wherein one ring system is a...  
WO/2016/019881A1
Disclosed is a method for preparing biocompatible, biodegradable microparticles having a controllable release profile for release of a biologically active agent contained in the microparticles. By adjusting the time period of treating th...  
WO/2016/020855A1
The invention describes the preparation of new grape seed extracts and their use in the treatment of various human pathological conditions, such as vascular diseases, cognitive disorders, depressive disturbances or clinical pictures of p...  
WO/2016/020786A1
The present invention is directed to compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein the substituents R1, R3, R6, R7, and b are as defined herein. The invention is also directed to pharmaceutical compositio...  
WO/2016/022724A1
The present invention provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula (I): wherein variables A4, A5, A6, A8, and each of Ra, Rb, R1, R2, R3 and R7...  
WO/2016/022521A1
Provided are novel compounds of Formula (I): pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are liver X receptor modulators, and which are useful in the treatment of diseases and disorders assoc...  
WO/2016/020854A1
The invention describes the preparation of new cocoa bean extracts and their use in the treatment of various human pathological conditions, such as vascular diseases, cognitive disorders, depressive disturbances or clinical pictures of p...  
WO/2016/017719A1
The present invention provides a method for manufacturing a compound of formula (I). Thus, provided is a 4-substituted-N-(2-phenyl[1,2,4]triazolo[1,5-a]pyridine-7-yl )-1H-pyrazole-5-carboxylic acid amide derivative manufacturing method o...  
WO/2016/015875A1
The present application describes a composition comprising apomorphine and a divalent metal cation in a molar ratio of 2 or less, a process for preparing the composition, a composition obtainable by said process, and the use of the compo...  
WO/2016/016395A1
The present invention relates to novel 6,7-dihydropyrazolo[1,5-a]pyrazin-4(5H)-one derivatives as negative allosteric modulators (NAMs) of the metabotropic glutamate receptor subtype 2 ("mGluR2"). The invention is also directed to pharma...  
WO/2016/016449A1
The invention relates to a method for the treatment of amyotrophic lateral sclerosis (ALS). Specifically, the invention implements the use of an antisense sequence adapted to affect alternative splicing in a human SOD1 pre-mRNA, thereby ...  
WO/2016/015203A1
Disclosed are a use of butenylphthalide for preparing a medicine and a method for preparing a pharmaceutical composition. Based on the fact that butenylphthalide has an ability to promote hair growth and reduce the content of beta-amyloi...  
WO/2016/017840A1
The present invention relates to a composition for relieving, suppressing, or treating chronic pain, the composition containing, as an active ingredient, a Gastrodia elata extract or a compound separated therefrom, and to a method for pr...  
WO/2016/016178A1
The invention relates to the use of a CXCR2 antagonist for the prevention and/or treatment of chemotherapy induced peripheral neuropathy (CIPN).  
WO/2016/018178A1
The invention relates to pharmaceutics and para-pharmaceutics, and more particularly to agents for the cessation of smoking. Proposed is a complex anti-nicotine agent, containing nicotine or a nicotine-like alkaloid and the amino acids t...  
WO/2016/019312A2
Disclosed herein are compounds that bind to the vesicular monoamine transporter 2 (VMAT2), pharmaceutical compositions comprising those compounds, and methods of treatment using said compounds and pharmaceutical compositions.  
WO/2016/019228A1
The present invention relates to indolizine compounds, and pharmaceutically acceptable compositions thereof, useful as antagonists of P2X7, and for the treatment of P2X7-related disorders.  
WO/2016/017767A1
Provided are: a novel Sirtuin-1 activator; and a preparation for preventing the occurrence of oxidative stress-induced cellular senescence, which contains the Sirtuin-1 activator. The present invention provides: a Sirtuin-1 activator whi...  
WO/2016/016382A1
The present invention relates to novel 6,7-dihydropyrazolo[1,5-a]pyrazin-4(5H)-one derivatives as negative allosteric modulators (NAMs) of the metabotropic glutamate receptor subtype 2 ("mGluR2"). The invention is also directed to pharma...  
WO/2016/016381A1
The present invention relates to novel 6,7-dihydropyrazolo[1,5-a]pyrazin-4(5H)-one derivatives as negative allosteric modulators (NAMs) of the metabotropic glutamate receptor subtype 2 ("mGluR2"). The invention is also directed to pharma...  
WO/2016/015378A1
Usage of a protein kinase inhibitor in preparing a neural cell from a differentiated non-neural cell is provided.  
WO/2016/019312A3
Disclosed herein are compounds that bind to the vesicular monoamine transporter 2 (VMAT2), pharmaceutical compositions comprising those compounds, and methods of treatment using said compounds and pharmaceutical compositions.  
WO/2016/016292A1
The present invention relates to compounds of formula (I), wherein L is a bond, -C(O)NH-, -NHC(O)-, -CH2NHC(O)-, CH2C(O)NH-, -CH2NH-, -NH- or -NHC(O)NH-; R1 is hydrogen, lower alkyl, halogen, lower alkoxy-alkyl, lower alkoxy substituted ...  
WO/2016/018178A4
The invention relates to pharmaceutics and para-pharmaceutics, and more particularly to agents for the cessation of smoking. Proposed is a complex anti-nicotine agent, containing nicotine or a nicotine-like alkaloid and the amino acids t...  
WO/2016/016383A1
The present invention relates to novel 6,7-dihydropyrazolo[1,5-a]pyrazin-4(5H)-one derivatives as negative allosteric modulators (NAMs) of the metabotropic glutamate receptor subtype 2 ("mGluR2"). The invention is also directed to pharma...  
WO/2016/018117A1
The present invention relates to an FK506 derivative which has no immunosuppressive activity but maintains nerve regeneration activity, a preparation method therefor, and a pharmaceutical composition comprising the same for preventing or...  
WO/2016/016380A1
The present invention relates to novel 6,7-dihydropyrazolo[1,5-a]pyrazin-4(5H)-one derivatives as negative allosteric modulators (NAMs) of the metabotropic glutamate receptor subtype 2 ("mGluR2"). The invention is also directed to pharma...  
WO/2016/016162A1
The present invention relates to a compound of formula (I), wherein L is –C(O)NH-, -NHC(O)-, -S(O)2NH-, -NH- or -NHC(O)NH-; Ar is phenyl, benzyl, naphthyl or heteroaryl, selected from the group consisting of pyridinyl, pyrazolyl, pyrim...  
WO/2016/016790A1
The present invention relates to an ester of a phospholipid with conjugated linoleic acid for use in the therapeutic treatment of or as a food supplement for psychiatric disorders with neuroinflammatory and neurodegenerative basis, such ...  
WO/2016/017826A1
Provided are: a xanthine oxidase inhibitor containing, as an active ingredient, a compound represented by formula (1) or a pharmaceutically acceptable salt thereof; an agent to improve endothelial function; and an agent suitable for the ...  
WO/2016/014982A1
Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds are contemplated for use in the treatment of diseases and disorders, such as learning, cognitive activities, and analgesia, parti...  
WO/2016/012384A1
The present invention provides a compound of formula I having BACE1 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the prese...  
WO/2016/011943A1
The present invention relates to a new benzodiazepine derivative, pharmaceutically acceptable salt thereof, preparation method therefor, and use thereof. The benzodiazepine derivative and the pharmaceutically acceptable salt thereof of t...  
WO/2016/013049A1
A packaged acetaminophen injection solution preparation (1) comprises an oxygen-impermeable packaging container (2) and an acetaminophen injection solution preparation including acetaminophen aqueous solution of pH 4 to 8 containing acet...  
WO/2016/014117A1
The present invention is focused primarily toward pro re nata ("as needed") treatments for the symptoms of panic and anxiety. The present invention encompasses pharmaceutical compositions as combination therapies containing at least one ...  
WO/2016/012896A1
The present invention is directed to compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein the substituents A, R1, R3, and b are as defined herein. The inventions also directed to pharmaceutical compositions comp...  
WO/2016/011931A1
The present invention relates to novel compounds that inhibit Lp-PLA2 activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases associated with the activity of Lp-PLA2, for e...  
WO/2016/014908A1
Bipartite molecules comprising a peptide affinity moiety and at least one charged moiety and uses thereof in reducing formation of abnormal protein aggregate and treating diseases associated with such abnormal protein aggregate, includin...  
WO/2016/012422A1
The present invention provides a compound of formula (I) having BACE1 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the pre...  
WO/2016/012916A1
The present invention relates to novel compounds that inhibit Lp‐PLA2 activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases or disorders associated with the activity of...  
WO/2016/012917A1
The present invention relates to novel compounds that inhibit Lp-PLA2 activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases or disorders associated with the activity of L...  
WO/2016/014847A1
Compounds are provided which bind to an allosteric site on the mammalian alpha-7 nicotinic acetylcholine receptor (alpha-7 nAChR) and act as positive allosteric modulators with or without allosteric agonist activity. The compounds are us...  
WO/2016/012657A1
The present invention relates to medicaments based on oligomeric forms of 3- hydroxybutyrate, particularly 3-hydroxybutyrate methyl ester dimer (1) and trimer (2), especially for use in treating, preventing and/or inhibiting development ...  
WO/2016/011535A1
Amorphous solid dispersions suitable for oral delivery comprising fenretinide or an analog thereof and at least one matrix polymer, and processes for making the dispersions, are disclosed. Also disclosed are solid oral formulations compr...  
WO/2016/013617A1
The present invention addresses the problem of providing a brain function improving agent and a prophylactic or therapeutic agent for cognitive dysfunction, each of which does not induce diarrhea and/or nausea, has a form that is easy to...  
WO/2016/011487A1
The present invention relates to polypeptides of SEQ ID NO: 1 (as well as biologically active derivatives thereof), that bind specifically to BACE1 and/or IL-4Rα. Compositions and methods incorporating the polypeptide of SEQ ID NO: 1 (o...  
WO/2016/011930A1
The present invention relates to novel compounds that inhibit Lp-PLA2 activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases associated with the activity of Lp-PLA2, for e...  
WO/2016/011979A1
The present invention relates to a 2,4-Disubstituted 7H-pyrrolo[2,3-d]pyrimidine derivative, a preparation method and a medicinal use thereof. In particular, the present invention discloses a compound of formula (I) or a pharmaceutically...  

Matches 501 - 550 out of 111,378